3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Gemcitabine
15
Cisplatin
9
Paclitaxel
6
Nivolumab
5
Fluorouracil
4
Carboplatin
4
atezolizumab
3
Sunitinib
3
Specimen Handling
3
Radiotherapy
3
Doxorubicin
3
pegfilgrastim
2
eribulin
2
cabozantinib
2
avelumab
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Ifosfamide
2
Docetaxel
2
CTLA-4 Antigen
2
Biopsy
2
vinflunine
1
vandetanib
1
tocilizumab
1
tamibarotene
1
rucaparib
1
rubitecan
1
romidepsin
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urethral Neoplasms
×
vinflunine
×
Clear all
NCT02665039
2019-10-08
VINGEM
Karolinska University Hospital
Phase 2
Completed
62 enrolled